Patents by Inventor Scott M. Walsh

Scott M. Walsh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES
    Publication number: 20230406959
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: April 28, 2023
    Publication date: December 21, 2023
    Inventors: Scott M. WALSH, Daniel B. DIX
  • Stabilized formulations containing anti-PCSK9 antibodies
    Patent number: 11673967
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: June 13, 2023
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Scott M. Walsh, Daniel B. Dix
  • Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
    Patent number: 11098127
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: August 24, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies
    Publication number: 20210230283
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: April 8, 2021
    Publication date: July 29, 2021
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES
    Publication number: 20210054100
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: July 16, 2020
    Publication date: February 25, 2021
    Inventors: Scott M. WALSH, Daniel B. DIX
  • Stabilized formulations containing anti-PCSK9 antibodies
    Patent number: 10752701
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: August 25, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Scott M. Walsh, Daniel B. Dix
  • Stabilized formulations containing anti-PCSK9 antibodies
    Patent number: 10472425
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: November 12, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Scott M. Walsh, Daniel B. Dix
  • STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES
    Publication number: 20190284301
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: April 15, 2019
    Publication date: September 19, 2019
    Inventors: Scott M. WALSH, Daniel B. DIX
  • Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies
    Publication number: 20190002574
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: August 9, 2018
    Publication date: January 3, 2019
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
    Patent number: 10072086
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: September 11, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Stabilized Formulations Containing Anti-PCSK9 Antibodies
    Publication number: 20180044436
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: May 24, 2017
    Publication date: February 15, 2018
    Inventors: Scott M. Walsh, Daniel B. Dix
  • Stabilized formulations containing anti-Ang2 antibodies
    Patent number: 9402898
    Abstract: The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to angiopoietin 2 (Ang-2). The formulations may contain, in addition to an anti-Ang-2 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stress.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: August 2, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Scott M. Walsh, Daniel B. Dix
  • Stabilized Formulations Containing Anti-PCSK9 Antibodies
    Publication number: 20160032015
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: October 20, 2015
    Publication date: February 4, 2016
    Inventors: Scott M. Walsh, Daniel B. Dix
  • Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies
    Publication number: 20160002341
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: September 22, 2015
    Publication date: January 7, 2016
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Stabilized formulations containing anti-PCSK9 antibodies
    Patent number: 9193801
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: November 24, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Scott M. Walsh, Daniel B. Dix
  • Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
    Patent number: 9173880
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: November 3, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Stabilized Formulations Containing Anti-PCSK9 Antibodies
    Publication number: 20140341928
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: June 30, 2014
    Publication date: November 20, 2014
    Inventors: Scott M. Walsh, Daniel B. Dix
  • Compositions and methods for treating bacteria
    Patent number: 8697639
    Abstract: The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compounds (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of using the same in research, therapeutic and drug screening applications.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: April 15, 2014
    Assignee: Biosynexus Incorporated
    Inventors: Scott M. Walsh, Mary C. Pittaway, James J. Mond
  • Stabilized Formulations Containing Anti-Ang2 Antibodies
    Publication number: 20130186797
    Abstract: The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to angiopoietin 2 (Ang-2). The formulations may contain, in addition to an anti-Ang-2 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stress.
    Type: Application
    Filed: January 22, 2013
    Publication date: July 25, 2013
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Scott M. WALSH, Daniel B. DIX
  • Stabilized Formulations Containing Anti-Interleukin-6 (IL-6) Antibodies
    Publication number: 20110171241
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: January 7, 2011
    Publication date: July 14, 2011
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. DIX, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh